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Abstract. In this study, we sought to determine the predictors of pathological complete response (pCR) and compare
the chemotherapeutic regimens administered to breast cancer
patients with and those without pCR. We retrospectively
reviewed the data of 879 patients treated at the Alvin J. Siteman
Cancer Center between 2006 and 2010, to identify patients
who were diagnosed with primary stage II or III breast cancer
and received neoadjuvant chemotherapy. Patients who received
only neoadjuvant endocrine therapy were considered to be ineligible. Patient, tumor, and treatment characteristics, including
type of chemotherapy, were compared between patients who
did and those who did not achieve pCR using Chi‑square or
Fisher's exact tests and multivariate logistic regression analysis.
Two‑sided P‑values of <0.05 were considered significant. Of
the 333 patients who met the inclusion criteria, 61 (18.3%) had
documented pCR. Compared with patients not achieving pCR,
a greater proportion of patients with pCR had stage II disease
(80.3 vs. 68%, P=0.057), had poorly differentiated (grade 3)
tumors (82 vs. 59.2%, P<0.001), had negative lymph node
involvement (41 vs. 34%, P=0.0004) and had tumors that were
HER2‑amplified (41 vs. 23.5%, P=0.0054). A greater proportion of patients with pCR received taxane‑based chemotherapy
(23 vs. 12.5%, P=0.016) or trastuzumab in conjunction with
chemotherapy (41.0 vs. 16.9%, P<0.001). No patients receiving
solely anthracycline‑based therapy achieved pCR in our study.
Our study demonstrated that, for stage II and III breast cancer,
lower stage, negative lymph node involvement and HER2
receptor amplification were each associated with pCR. Taxane
therapy and the concurrent use of trastuzumab were also associated with a higher likelihood of pCR.
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Neoadjuvant chemotherapy for the treatment of breast cancer
has undergone significant evolution over time. Historically,
neoadjuvant chemotherapy was used only for tumors considered inoperable at presentation. However, this changed after
the publication of the well‑known National Surgical Adjuvant
Breast and Bowel Project study results, which demonstrated
that neoadjuvant chemotherapy, in comparison to adjuvant,
was not associated with significant differences in disease‑free
or overall survival and was associated with higher rates of
breast‑conserving surgery (1,2). Neoadjuvant chemotherapy
use was subsequently broadened to include large, operable
tumors with the aim of achieving breast conservation.
In addition to breast conservation, neoadjuvant chemotherapy allows for an in vivo assessment of response to therapy,
while also providing early treatment of the primary tumor and
potential micrometastatic disease (3). Pathological complete
response (pCR), often used as a surrogate endpoint to assess
the efficacy of neoadjuvant chemotherapy, is also considered to
be a strong prognostic measure of long‑term clinical outcomes,
including disease-free and overall survival (4‑6). Hence, identifying and validating factors which predict pCR or improve
pCR rates are crucial in breast cancer management.
Furthermore, anthracyclines have been considered traditionally as the most standard and active among breast cancer
chemotherapy drugs. In an effort to improve pCR rates, other
studies investigated the impact of combining different chemotherapeutic agents in the neoadjuvant setting (7‑10). In our study,
we not only sought to identify pCR rates and predictors at a
single institution, but also to examine the administered chemotherapeutic regimens, and compare and contrast the regimens
between patients who did and those who did not achieve pCR.

Patient selection. During a retrospective review of 879 patients
who were treated for a first primary breast cancer at the
Alvin J. Siteman Cancer Center between January, 2006 and
December, 2010, we identified patients who received neoadjuvant chemotherapy for pathologically confirmed invasive
(stage II and III) breast cancer. We restricted our analysis to
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stage II and III disease in the specified 5‑year period in order to
evaluate a more homogeneous population of patients receiving
neoadjuvant chemotherapy, with or without other neoadjuvant
treatment, as neoadjuvant treatment decisions were likely
made based on similar overarching guidelines during this
period (based on tumor size and grade, presence or absence
of lymph node metastases, receptor status and recommended
chemotherapeutic regimens). The medical records of patients
who received neoadjuvant chemotherapy were reviewed, to
determine which of these patients' tumors exhibited a pCR,
defined as no evidence of residual invasive malignancy in the
breast or axilla. As ductal carcinoma in situ (DCIS) generally
does not regress with chemotherapy and evidence of its impact
on prognosis is equivocal (11,12), patients with only residual
DCIS following neoadjuvant systemic therapy were included
in the pCR cohort. Patients who received only neoadjuvant
endocrine therapy without mention of chemotherapy in the
neoadjuvant setting were deemed ineligible for inclusion,
mainly to avoid including patients who rarely achieve pCR, as
previous studies have demonstrated that, while a large number
of patients undergoing neoadjuvant endocrine therapy display
some evidence of clinical response, pCR is infrequent (13‑16).
Additionally, we determined the specific neoadjuvant systemic
therapy received by each of the identified patients to assess
the potential impact of the chemotherapeutic regimen received
on the pCR rates observed. The regimen administered to each
patient was selected at the discretion of the medical oncologist,
based on established standards or clinical trials in place at the
time of therapy.
This study was initiated after Institutional Review Board
approval was obtained, with a waiver of consent given the
retrospective nature of the study.
Statistical analysis. We used the Wilcoxon rank‑sum tests
(for continuous variables), Chi‑square or Fisher's exact tests
(for categorical variables) and unadjusted logistic regression
to examine clinical characteristics potentially associated with
pCR, including age, race, lymph node involvement, histology,
TNM stage, tumor grade, estrogen receptor (ER) and progesterone receptor (PR) status, and presence of HER2 amplification.
Tumor size was not examined as a discrete variable, but rather
as a component of stage. Biomarker/receptor status, stage and
factors significant at P<0.2 in unadjusted tests were included
as independent variables in multivariate logistic regression
models that were further refined using backwards elimination.
Two regression models for the outcome pCR as a
yes/no binary measure were created, one featuring each
individual receptor status (i.e., PR, HER2) and the other
using a composite biomarker status reported of hormone
receptor status plus/minus HER2 amplification. A hormone
receptor‑positive (HR+) cancer was defined as an ER‑positive
and/or PR‑positive cancer, whereas a hormone receptor‑negative (HR‑) cancer was defined as an ER‑negative and/or
PR‑negative cancer. These definitions led to the generation
of four categories for comparison in the composite biomarker
analysis as follows: HR+/HER2‑, HR+/HER2+, HR‑/HER2‑
and HR‑/HER2+. Additionally, grade was analyzed by
combining well‑ and moderately differentiated cancers
(grade 1 and 2) and comparing them to poorly differentiated cancers (grade 3). We report adjusted odds ratios (ORs)

and 95% confidence intervals (CIs) significant at two‑tailed
P<0.05. The statistical analyses were conducted using SAS 9.3
software (SAS Institute Inc., Cary, NC, USA).
Results
pCR rates and predictors. Over the 5‑year period reviewed,
333 patients received neoadjuvant chemotherapy. Among these
patients, the majority had stage II disease (70.3%) and tumors
that were ER+ (52.3%), PR‑ (55.9%), HER2‑non‑amplified
(HER2‑; 73.3%), poorly differentiated (i.e., grade 3; 63.4%),
and a ductal histology (77.5%). A total of 61 patients (18.3%)
had pCR. Descriptive statistics of the study sample grouped by
pCR status are shown in Table I.
In unadjusted tests, pCR was associated with higher tumor
grade (P=0.0035), no lymph node involvement (P=0.0013),
HER2 amplification (P= 0.0061), ER‑negative (P=0.027) and
PR‑negative status (P<0.001). Also observed was an inverse
association between pCR and HR+/HER2- status (P<0.001).
These results are shown in Table II.
The results of separate multivariate logistic regression
models, one featuring individual biomarkers and the other
including composite biomarkers, are also reported in Table II.
In the model featuring individual biomarkers, HER2 amplification (P=0.0095), PR‑negative status (P=0.0081) and absence of
lymph node involvement (P=0.0039) predicted a higher likelihood of pCR. In the multivariate model including the composite
biomarkers, the HR+/HER2‑ subtype and any lymph node
involvement (P=0.0049) resulted in a lower likelihood of pCR.
Neoadjuvant systemic therapy. Of the 333 patients in the study
sample, complete records of the administered chemotherapeutic regimens were available for 323 (97%); 252 patients
received a combined regimen of anthracyclines and taxanes,
48 received a taxane‑only regimen, 19 received an anthracycline‑only regimen and 4 received a platinum agent‑based
regimen. Following completion of all the cycles of neoadjuvant
chemotherapy, 46/252 patients receiving combined regimen of
anthracyclines and taxanes, 14/48 patients in the taxane‑only
subgroup, 1/4 patients receiving platinum agent‑based therapy
and none of the patients (0/19) in the anthracycline‑only
subgroup exhibited pCR (P=0.016). Furthermore, administration of neoadjuvant therapy with or without trastuzumab
was recorded for 329 (98.8%) patients; 71 patients (21.3%)
received trastuzumab, either concomitant with or sequential
to chemotherapy, while 258 patients did not receive trastuzumab. Following completion of all the cycles of trastuzumab
treatment, 25/71 patients exhibited pCR (compared to 36/258
patients with pCR in the no‑trastuzumab subgroup, P<0.001).
The data on neoadjuvant systemic therapy are summarized in
Table III and Fig. 1.
Discussion
The results of our unadjusted analyses are in line with previously reported associations between pCR and higher tumor
grade and the presence or absence of particular biomarkers. In
our multivariate analysis, HER2 amplification, PR status and
lack of lymph node involvement were found to be significant
predictors of pCR.

MOLECULAR AND CLINICAL ONCOLOGY 3: 1117-1122, 2015

1119

Table I. Baseline patient and tumor characteristics.
		pCR,
All patients
no. (%)
Characteristics
(n=333)
(n=61)

No pCR,
no. (%)
(n=272)

P-value

Age, years [median (range)]
48 (20-83)
48 (27-70)
48 (20-83)
0.8
Race				0.9612
Caucasian
233 (70.0)
43 (70.5)
190 (69.9)
African American
93 (27.9)
17 (27.9)
76 (27.9)
Other
7 (2.1)
1 (1.6)
6 (2.2)
Stage				0.0572
II
234 (70.3)
49 (80.3)
185 (68.0)
III
99 (29.7)
12 (19.7)
87 (32.0)
Histology				0.0582
IDC
258 (77.5)
56 (91.8)
202 (74.3)
ILC
22 (6.6)
1 (1.64)
21 (7.7)
Mixed IDC and ILC
20 (6.0)
1 (1.64)
19 (7.0)
Inflammatory
18 (5.4)
1 (1.64)
17 (6.2)
Other
15 (4.5)
2 (3.28)
13 (4.8)

Grade				0.00065
1 and 2
119 (35.7)
10 (16.4)
109 (40.1)
3
211 (63.4)
50 (81.96)
161 (59.2)
Unknown
3 (0.9)
1 (1.64)
2 (0.7)
Individual biomarkers
Estrogen				
0.026
ER+
174 (52.3)
24 (39.3)
150 (55.15)
ER159 (47.7)
37 (60.7)
122 (44.85)
Progesterone				
0.0007
PR+
147 (44.1)
15 (24.6)
132 (48.5)
PR186 (55.9)
46 (75.4)
140 (51.5)
HER2				
0.0054
HER2+
89 (26.7)
25 (41.0)
64 (23.5)
HER2244 (73.3)
36 (59.0)
208 (76.5)
Composite biomarkers				
0.0007
HR+/HER2+
54 (16.22)
15 (24.6)
39 (14.3)
HR-/HER2+
35 (10.51)
10 (16.4)
25 (9.2)
HR+/HER2130 (39.04)
10 (16.4)
120 (44.1)
HR-/HER2114 (34.23)
26 (42.6)
88 (32.4)
Lymph node involvement				
0.0004
None
117 (35.14)
25 (41.0)
92 (33.82)
Any
100 (30.03)
6 (9.8)
94 (34.56)
Unknown
116 (34.6)
30 (49.2)
86 (31.62)
pCR, pathological complete response; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

Overexpression of HER2, a receptor‑like tyrosine kinase,
is shared by multiple human carcinomas; however, HER2
amplification in breast cancer is of particular significance
in determining therapy and predicting outcome. Present in
20‑30% of all breast cancers, HER2 amplification potentiates
growth dysregulation, oncogenesis and metastasis, all of which
contribute to its association with lower disease‑free and overall

survival. Tumors that overexpress HER2 are also more likely
to be chemoresistant, hence the importance of trastuzumab,
a HER2‑targeting drug, which was first approved by the
Food and Drug Administration in 1998 in the management
of these cancers (17). In our study, HER2 overexpression
was predictive of pCR in the multivariate model containing
individual biomarkers, thus allowing for ER, PR, and HER2
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Table II. Unadjusted and multivariate logistic regression analyses identifying independent predictors of pCR following neoadjuvant chemotherapy.
			
Unadjusted analyses		
------------------------------------------------------------Variables
OR (95% CI)
P-value
Ageb
ERER+
PRPR+
HER2HER2+
Grade 1 and 2
Grade 3
Stage II
Stage III
No LNI
Any LNI
HR+/HER2+
HR+/HER2HR-/HER2+
HR-/HER2-

Multivariate analysis 1		
using composite biomarkersa
-----------------------------------------------------------OR (95% CI)
P-value

0.997 (0.97-1.02)
0.83
0.99 (0.97-1.02)
0.56
1.00 (reference)				
0.53 (0.3-0.93)
0.027
-		
1.00 (reference)				
0.35 (0.18-0.65)
<0.001
-		
1.00 (reference)				
2.26 (1.26-4.04)
0.0061
-		
1.00 (reference)		
1.00 (reference)		
3.39 (1.65-6.96)
0.0035
2.01 (0.86-4.72)
0.48
1.00 (reference)		
1.00 (reference)		
0.52 (0.26-1.03)
0.060
0.60 (0.27-1.32)
0.096
1.00 (reference)		
1.00 (reference)		
0.24 (0.092-0.60)
0.0013
0.32 (0.12-0.86)
0.0057
1.00 (reference)				
0.21 (0.078-0.55)
<0.001
0.27 (0.11-0.67)
0.0045
0.96 (0.37-2.47)
0.099
0.95 (0.34-2.65)
0.20
0.74 (0.31-1.74)
0.43
0.59 (0.26-1.33)
0.84

Multivariate analysis 2
using individual biomarkers
----------------------------------------------------------OR (95% CI)
P-value
0.99 (0.96-1.02)
1.00 (reference)
1.59 (0.64-3.92)
1.00 (reference)
0.28 (0.11-0.72)
1.00 (reference)
2.34 (1.23-4.46)
1.00 (reference)
2.28 (1.0-5.14)
1.00 (reference)
0.48 (0.23-1.02)
1.00 (reference)
0.28 (0.11-0.79)
1.00 (reference)
-

0.47
0.32
0.0081
0.0095
0.14
0.057
0.0039

The composite biomarkers assessed in regression model were HR+/HER2+, HR+/HER2-, HR-/HER2+ and HR-̸HER2-. bAnalyzed as a
continuous variable. pCR, pathological complete response; OR, odds ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone
receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; LNI, lymph node involvement.
a

Table III. Neoadjuvant systemic therapy received based.
		
All patients
Characteristics
(n=333)

pCR
no. (%)
(n=61)

No pCR
no. (%)
(n=272)

Trastuzumab therapy				
Yes
71 (21.3)
25 (41.0)
46 (16.9)
No
258 (77.5)
36 (59.0)
222 (81.6)
Unknown
4 (1.2)
0 (0.0)
4 (1.5)
Chemotherapy grouping				
Anthracyclines and taxanes
252 (75.7)
46 (75.4)
206 (75.7)
Anthracycline-based
19 (5.7)
0 (0.0)
19 (7.0)
Taxane-based
48 (14.4)
14 (23.0)
34 (12.5)
Platinum agent‑based
4 (1.2)
1 (1.6)
3 (1.1)
Unknown
10 (3.0)
0 (0.0)
10 (3.7)

P-value
<0.001

0.0161

pCR, pathological complete response.

statuses to be directly controlled for in relation to one another.
In the model with composite biomarkers, we also observed
that the ER+/PR+/HER2‑ subtype was negatively associated
with pCR. The aggregate of these findings suggests that there
may be a complex interplay between the tumor biology and
treatment with trastuzumab. In reference to pCR rates, we are

currently unable to disentangle the potential biological effects
of HER2 amplification from the potential benefits gained from
trastuzumab treatment. Additional prospective studies are
required to elucidate this matter.
Lack of lymph node involvement was also found to be a
significant predictor of pCR in patients with HER2 amplification
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Figure 1. Chemotherapeutic regimen used in patients with or without pathological complete response (pCR).

without ER or PR expression, even after adjusting for stage
in the regression model. Lymph node involvement at initial
presentation is a well‑established outcome prognosticator in
breast cancer and patients with breast pCR but residual nodal
disease have lower rates of overall survival compared with
patients who experience breast as well as nodal pCR (1,18).
The assessment of the type of neoadjuvant systemic therapy
received, highlights the fact that the majority of the treated
patients at our institution received the standard recommended
regimen, while also exhibiting improved pCR rates when
taxanes are used or added to anthracycline therapy. Multiple
trials evaluating a broad range of chemotherapy drugs have
also demonstrated that the use of anthracyclines in combination with taxanes is associated with improved pCR rates (7,10).
Hence, the consensus statement of the St. Gallen Conference,
states that a standard neoadjuvant chemotherapy regimen
should include both an anthracycline and a taxane (19).
Platinum agents are DNA‑damaging agents, which have
been found to be particularly beneficial in improving pCR
rates in triple‑negative breast cancer (TNBC), particularly
BRCA‑mutated tumors (which represent up to 50% of all
TNBCs). In a meta‑analysis of 28 studies, the pooled pCR
rate noted following addition of a platinum agent to a standard
neoadjuvant chemotherapy regimen for TNBC was 45% (20).
Another single‑institution study reported pCR rates of 22%
following neoadjuvant treatment with single‑agent cisplatin
therapy in patients with stage II or III TNBC (21). In our study,
all 4 patients receiving platinum agents had TNBC and they
received single‑agent therapy with the platinum agent. Of note,
the sole patient exhibiting pCR following administration of the
platinum agent had a higher tumor grade (grade 3), lower stage
(stage II) and no lymph node involvement. To the best of our
knowledge, a review of the literature has retrieved no data to
suggest that the improvement in pCR rates following addition
of platinum agents to standard neoadjuvant chemotherapy
in TNBC translates to improvements in overall survival or
disease‑free survival. More studies are required to evaluate the

potential survival benefits of adding platinum‑based therapy to
standard neoadjuvant chemotherapy for patients with TNBC.
Our study had certain limitations. First, we were unable
to establish causation, but could only show association, due
to the fact that retrospective studies are prone to patient and
treatment selection bias. Additionally, potential confounding
variables may not always be recognized or recorded, due to
a lack of knowledge regarding how they interact with the
outcome of interest. Second, we were unable to control for
administration of trastuzumab therapy with regard to the association of HER2 amplification with pCR. As the provision of
HER2‑targeted therapy has recently become more standardized, future prospective studies will undoubtedly be better
equipped to investigate this issue. Third, all the patients in our
study were treated at a high‑volume, NCI‑designated comprehensive cancer center, although the majority of the patients in
this country obtain their chemotherapy from non‑academic,
community medical oncologists. This may translate to potential differences in patient population, treatment received,
treatment duration, or even the definition of pCR; thus, the
extent to which our patients exhibit pCR and the reasons why
they do so, may not reflect the experience of breast cancer
patients receiving care outside a comprehensive cancer center.
Finally, details regarding the optimal chemotherapy dose,
treatment duration, or concurrent vs. sequential administration
for improving pCR rates were not obtained in this study. Other
studies are currently underway, however, to address optimal
administration times in the neoadjuvant setting to improve
pCR rates.
In conclusion, we found in the regression model using the
composite HR variable that HR+/HER2- tumors were significantly less likely to undergo pCR compared with HR+/HER2+
tumors, and that tumors with any lymph node involvement were
significantly less likely to undergo pCR compared with tumors
without lymph node involvement. Additionally, we found that
the pCR rates were higher among patients receiving trastuzumab or taxane therapy in addition to anthracycline therapy.
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